Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

nts with ESRD on dialysis are usually associated with secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and the progression of renal failure. ESRD patients usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. The need for alternative phosphate-binding agents has long been recognized, especially given the increasing prevalence of ESRD as well as shortcomings with current therapies. Zerenex has the potential to be an effective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

The market for phosphate binders to treat hyperphosphatemia in ESRD patients in 2010 was approximately $750 million in the U.S. and is approaching $1.5 billion worldwide.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other signal transduction pathways, including the JNK pathway, believed to be associated with cell death, growth, differentiation and survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphate
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... The laboratory information management systems market ... number of technological advancements due to factors such as ... to integrate healthcare systems, and increasing government support for ... integration. Key players in the market focus on technological ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics ... from a new partner. STT-Systems has developed an ... years, with offerings in the optical-motion capture, 3D scanning, and ... measurement unit), iSen, is opening eyes around the world. With ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2
... Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: ... rights to seven key patents from Company CEO Dr. ... will significantly enhance Sinobiopharma,s ability to execute on its ... patents are for the following:, ...
... April 27 /PRNewswire/ - In connection with the requisition ... "Concerned Shareholders") relating to the annual and special meeting ... on May 28, 2009 (the "Meeting"), the Concerned Shareholders ... forward for election as directors at the Meeting are ...
... Spherix Incorporated (Nasdaq: SPEX ), an ... of technical and regulatory consulting services to food, supplement, ... 23, 2009, it received written notification from NASDAQ that ... independent director rule. Spherix fell out of compliance ...
Cached Biology Technology:Sinobiopharma Secures Rights to Seven Key Patents 2Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail 2Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail 3Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail 4Spherix Recruiting New 'Independent' Director to Regain NASDAQ Compliance 2Spherix Recruiting New 'Independent' Director to Regain NASDAQ Compliance 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... are a staple crop of Rwanda. The fruit is eaten raw, ... Around 2 million tons are grown each year but the fruit ... rest skins, leaves and stems is left to rot ... looking at ways to use that waste to produce fuel, developing ...
... Russ Miller is leading the rollout of "Magic," one ... to qualified users worldwide for solving computationally-demanding problems. ... Previously Unsolvable Problems , Cyberinfrastructure sits at the ... methods of investigation that allow scholars to address previously ...
... 50 people in Japan suggests that eating two and a ... confer some protection against a rampant stomach bug that causes ... new "demonstration of principle" study, a Johns Hopkins researcher and ... sulforaphane did not cure infection by the bacterium Helicobacter ...
Cached Biology News:Going bananas for sustainable research -- scientists create fuel from African crop waste 2Collaboration leads to success: Most powerful computer of its kind in western N.Y. available worldwide 2Collaboration leads to success: Most powerful computer of its kind in western N.Y. available worldwide 3Collaboration leads to success: Most powerful computer of its kind in western N.Y. available worldwide 4Gutsy germs succumb to baby broccoli 2Gutsy germs succumb to baby broccoli 3Gutsy germs succumb to baby broccoli 4
... The first high-density serum biomarker chip to ... proteins. An antibody chip containing 120 human ... that enables biomarker discovery scientists to study ... benefits of therapy and the likelihood of ...
... The Costar strip ejector is a unique ... Costar strips from their holder. Linkage: This ... created to easily match Cornings product number. ... under the old Sigma-Aldrich number (Z71,314-7) or ...
...
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
Biology Products: